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APOLOGIA. 
In medical terminology the word 'diagnosis' means the 
determination of the nature of a diseased condition. In 
the past it was sufficient to identify a disease by a 
constellation of symptoms and signs and this is still 
of pre -eminent importance - but it is becoming increa- 
singly common to use ancillary aids to diagnosis as 
these are developed by modern scientific method. It is 
always difficult to predict the possible applications 
of 'pure' investigative research but we suggest that 
the work described in the following paper may prove to 
be relevant to the diagnosis of Parkinsonism, using 
biochemical estimations in the cerebro- spinal fluid of 
homovanillic acid and 5- hydroxyindol- 3- ylacetic acid, 
metabolites of the cerebral amines dopamine and 5- hydroxy- 
tryptamine respectively. 
This work, which constituted part of a thesis submitted 
for the degree of Ph.D., was carried out in the Depart- 
ments of Pharmacology and Surgical Neurology. I am 
grateful to Professor W.L.M.Perry and Professor F.J. 
Gillingham for their help and encouragement and to 
Mr. J. W. Turner who collected the samples of ventri- 
cular cerebro- spinal fluid. 
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INTRODUCTION. 
The syndrome of Parkinson's disease has been asso- 
ciated with changes in concentrations of certain cerebral 
amines, in particular that of dopamine. Estimations of 
the dopamine content of various brain regions, post- 
mortem, of patients who had suffered from Parkinson's 
disease and post- encephalitic Parkinsonism have shown 
that the concentration of this amine was most markedly 
decreased in the basal ganglia (Ehringer and Hornykiewicz, 
1960; Hornykiewicz, 1962). Very low concentrations of 
dopamine were -found in the caudate nucleus, putamen and 
globus pallidus, particularly so in the post -encephalitic 
cases. The substantia nigra of Parkinsonian patients has 
also been shown to contain sub -normal amounts of dopamine 
(Hornykiewicz, 1963). The same worker also observed a 
moderate decrease in the noradrenaline content of the 
hypothalamus, and the 5- hydroxytryptamine concentration 
was reported to be lower than normal in several brain 
regions of Parkinsonian patients (Bernheimer, Birkmayer 
and Hornykiewicz, 1961). The concentrations of noradren- 
aline and 5- hydroxytryptamine were, however, never so 
markedly decreased as that of dopamine. 
The suggestion that Parkinsonism is associated with 
an error in dopamine metabolism was substantiated by 
the observation that Parkinsonian patients excreted less 
dopamine in the urine than normal controls (Barbeau, 
Murphy and Sourkes, 1961; Bischoff and Torres, 1962). 
Studies on some of the metabolites from the amines 
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have also been reported in Parkinsonism. Homovanillic 
acid (HVA), the main metabolite from dopamine, has been 
shown to occur in the corpus striatum, the globus 
pallidut; and the substantia nigra of the brain from 
Parkinsonian patients in markedly decreased concentrations 
(Bernheimer and Hornykiewicz, 1964). This acid metabolite 
has also been found to be present in significantly lower 
concentrations in lumbar C.S.F. from patients with 
Parkinsonism than from a control group. (Bernheimer, 
Birkmayer and Hornykiewicz,. 1966). 
The urinary outputs of HVA as well as of 5- hydroxy- 
indol-3- ylacetic acid (5- H1AA), the acid metabolite from 
5- hydroxytryptamine, have been estimated in Parkinsonian 
patients. The excretion òf HVA was reported to be normal 
(Greer and Williams, 1963). Barbeau and Jasmin (1961) 
found that the excretion of 5 -H1AA was lower than normal, 
but this finding was not confirmed by Resnick, Gray, Koch 
and Timberlake (1962). 
A study has been made, with the results reported below, 
of the concentrations of HVA and 5 -H1AA in the ventricular 
C.S.F. of patients who were undergoing stereotaxic surgery 
for the relief of Parkinsinism. The patients making up 
the control group were undergoing cerebral ventricular 
catheterisation as a diagnostic or therapeutic procedure 
and they had no clinical evidence of disease of the 
extrapyramidal system. The biochemical findings are 
discussed in relation to various clinical observations. 
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Materials and Methods. 
Patients with Parkinsonism. 
The subjects of the study were patients admitted to 
Western General Hospital, Neurosurgical Unit (S.N.3), 
Edinburgh, who were undergoing stereotaxic surgery for 
the relief of Parkinsonism (Gillingham, Watson,Donaldson 
and Naughton, 1960). There was no selection of these 
patients beyond the criteria for selection of the 
Parkinsonian patient for operation. A few results were, 
however, excluded from the final analysis, and this 
problem is discussed later in conjunction with the diffi- 
culties in sampling of the ventricular C.S.F. and some 
technical aspects associated with the biochemical 
analysis of the C.S.F. samples. Thirty -seven patients 
suffering from Parkinsonism have been included in this 
survey. Clinically it was found difficult to differ- 
entiate between the various types of Parkinsonism, but 
most of the cases were thought to be suffering from 
idiopathic Parkinson's disease while a few were of the 
post -encephalitic type. Arteriosclerosis can be a 
contributing factor in the development of Parkinsonism, 
but none of the patients showed obvious clinical 
evidence of arteriosclerosis. 
In about one -third of all the patients, all drugs, 
except paracetamol for the relief of headaches, were 
stopped. The drugs were discontinued before or on 
arrival of the patient at the hospital and the minimum 
period between stopping the drugs and the start of the 
'study was 48 hours. This discontinuation of drugs was 
adhered to for all the cases admitted for surgery during 
a certain period of time. In the remaining two -thirds 
of the patients the medical treatment of Parkinsonism 
was continued over the period of study. The drug 
treatment consisted of one of the following anticholinergic 
drugs: Benzhexol (Artane), Benztropine (Cogentine) or 
Orphenadrine (Disipal). 
In addition to one of the anticholinergic drugs, 4 patients 
were being treated with antidepressants, 2 patients with 
amitriptyline and 2 with imipramine. One patient was also 
treated with probenecid in addition to benztropine. The 
patients continuing drugs were allowed sedative drugs at 
night as well as a variety of mild analgesics. The only 
drugs used at operation were local anaesthetics for 
anaesthetising the skin. No specific dietary restrictions 
were instituted. 
The patients were assessed carefully preoperatively 
with regard to certain of their symptoms, in particular, 
the extrapyramidal symptomatology of tremor, rigidity and 
akinesia. The degree of tremor and rigidity was graded 
clinically (0 to + + + +) for both sides of the body and 
akinesia, defined as "difficulty to initiate voluntary 
movements ", recorded as present or absent. Age and sex 
of the patient was recorded, and, in most cases, an 
attempt was made to find out the duration of the illness 
to the nearest year. The patients were also questioned 
closely as to the occurrence of encephalitis or "severe 
flu" in the past history. In only 2 cases did we obtain 
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a definite history of encephalitis ; in a further case 
there was a past history of "severe flu" and in the fourth 
case there was a history of the onset of Parkinsonism 
following desensitization for an allergy. These four 
cases have arbitrarily been defined as suffering from 
post- encephalitic Parkinsonism. A clinician was respons- 
ible for the clinical assessments of the patients and 
the person responsible for the biochemical analyses 
was unaware of the clinical facts until the end of the 
study. 
Patients suffering from dystonias other than Parkinsonism. 
A small group of patients (5 cases) suffering from 
dystonias of types different from that of Parkinsonism 
was also included as a pilot study. The diagnosis in 2 
of these was: "torsion dystonia" ; 2 cases were diagnosed 
as: "spasmodic torticollis" and the fifth case as: 
"familial tremor ". This group has not been included in 
the final analysis of the main study. 
Patients in the "control group" 
These patients were undergoing cerebral ventricular 
catheterisation, usually as a diagnostic procedure for 
ventriculography and, less commonly, as a therapeutic 
procedure for the drainage of C.S.F. as in hydrocephalus 
or to perform frontal lobectomy as in the psychiatric 
cases. Seventeen cases were included in the final series, 
11 from the same hospital as the Parkinsonian patients 
and 6 from the Head Injury Unit situated in the Royal 
Infirmary of Edinburgh. Most of the cases were suffering 
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from organic disease, 5 cases of cerebral tumours, 3 cases 
of subarachnoid haemorrhage, 3 cases of hydrocephalus 
and 3 cases of head injuries. There were 3 patients 
with psychiatric disease, (Table 3). The only criterion 
for selection of the type of case to be included was the 
absence of any clinical evidence of disease of the 
extrapyramidal system. 
Originally, the control -group consisted of 21 cases, 
but 4 cases had to be excluded for the following reasons. 
Examination] of the x -ray photographs for the position of 
the catheter through which the C.S.F. was obtained, in 3 
cases showed that the tip of the catheter was found to be 
in the aqueduct or the 4th ventricle or the region of the 
cisterna magna. There is normally a marked concentration 
difference for HVA and 5 -H1AA between lateral ventricular 
and cisternal C.S.F. in the dog (Guldberg, Ashcroft and 
Crawford, 1966) and this appeared also to be the case in 
man. One case had to be excluded because the C.S.F. 
sample contained haemolyzed blood and the blood pigments 
were found to interfere with the estimations of HVA. 
Similarly, the xanthochromia of the C.S.F. from two of 
the patients with subarachnoid haemorrhage, made it 
necessary to exclude these samples from the HVA estimates. 
It was not practically possible to stop drug treatment 
in the control patients. 
Collection of ventricular C.S.F. samples. 
All the C.S.F. samples were collected into chemically 
clean, graduated, glass stoppered test tubes. The volume 
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of C.S.F. withdrawn at any one time was 4 ml. The samples 
were stored at -20 °C. until the analysts could be performed, 
usually, on the following day. If traumatic bleeding into 
the C.S.F. had occurred the sample was centrifuged and the 
cell free supernatant decanted into a clean test tube. 
C.S.F. sampling in Parkinsonian cases. 
(1) 4 ml. of C.S.F. was withdrawn from the lateral 
ventricle following the introduction of the catheter at 
"stage 1" of the operation (sample Al). This was an 
important base -line sample. 
In addition, it was decided to investigate in a few 
cases the effect on the concentration of HVA and 5 -H1AA 
of repeated sampling, by withdrawing in rapid succession 
another two samples each of 4 ml. of C.S.F. (samples 
A2 and A3). 
(2) On the day of therapeutic operation, "stage 2" 
of the operation which was generally 2 days after stage 
1, a 4 ml. sample of C.S.F. was again withdrawn at the 
onset of the operation (sample B1). A further sample 
was withdrawn about 0,5 hr.' later (sample B2) after the 
intraventricular injection of the radio- opaque material 
"Myodil ". Another sample of the C.S.F. (sample B3) was 
withdrawn after destruction of the target areas. The 
target areas were commonly the ventrolateral nucleus 
of the thalamus and /or the globus pallidus and /or 
internal capsular fibre connections. 
(3) In several patients the ventricular catheter 
was left in situ for another 3 days and the final sample 
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of 4 ml. of ventricular fluid withdrawn before removal 
of the catheter, "stage 3" of the operation. This sample, 
(C1), was most important for the study of possible 
biochemical changes occurring in the C.S.F. following 
the operational therapy. 
In each case a record was kept of the target area 
for the operation and the clinical assessment of the 
therapeutic result of the operation. 
At the end of the study, all the x -rays were viewed 
to determine the position of the catheter from which the 
samples were taken. The burr -holefor the ventricular 
catheter was always made on the right side of the skull. 
In most cases the catheter was found to be placed in the 
right lateral ventricle, but sometimes it was found to be 
situated in the left lateral ventricle and on occasions 
in the third ventricle or at the foramen of Munro. 
C.S.F. sampling from the "control" cases. 
In this group, comprising the non -Parkinsonian cases 
with no clinical evidence of disease of the extrapyramidal 
system, 4 ml. of C.S.F. was collected from the lateral 
ventricle in exactly the same way as for the Parkinsonian 
cases (samples Al). C.S.F. was withdrawn immediately 
following the introduction of the catheter, and in no 
case was any C.S.F. withdrawn just previous to the sample. 
Generally, only a single sample was obtained from each 
control patient except in 3 psychiatric patients under- 
going the operation of frontal lobectomy, when C.S.F. 
samples were collected during the operation. 
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Estimation of HVA and 5 -H1AA in ventricular C.S.F. 
The estimations of the phenolic acids were carried 
out on 2,0 ml. samples of C.S.F. A technically simple 
procedure was adapted from existing methods to permit 
the estimation of the two acids, HVA and 5 -H1AA, in a 
single sample of the lateral ventricular C.S.F. This 
procedure was analogous to that for ventricular C.S.F. 
from the dog and the details of the procedure have been 
described elsewhere (Guldberg,1967). The C.S.F. was 
acidified to pHK2with concentrated HC1, saturated with 
sodium chloride and the acids extracted into 2 vol.ethyl 
acetate, by shaking the mixture for 5 min. The phases 
were separated by centrifugation for 5 min. The ethyl 
acetate extraction was repeated and the acids in the 
pooled ethyl acetate extracts were back -extracted into 
2,2 ml. O,1M "tris" buffer, pH 8,6. Each acid was 
estimated fluorimetrically in separate aliquots of 1 ml. 
of this extract. HVA was estimated by the method 
described by Andan, Roos and Werdinius (1963) and 5 -H1AA 
by the method of Ashcroft and Sharman (1962). Recoveries 
of 200 mp.g. of HVA and 5 -H1AA taken through the entire 
procedure were of the order of 95% for HVA and 85% for 
5 -H1AA. The estimates of the acids in the C.S.F. samples 
have not been corrected for recoveries. It was discovered 
that if the C.S.F. sample for analysis contained appreci- 
able amounts of blood pigments, these would interfere 
with the fluorimetric estimation of HVA. The results 
from such samples had to be discarded. 
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Fig. 1. Frequency distribution for the 
homovanillic 
acid (HVA) and 5- hydroxyindol- 3- ylacetic 
acid 
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RESULTS. 
HVA and 5 -H1AA in the C.S.F. from Parkinsonian patients. 
We estimated the mean concentrations of HVA and 
5 -H1AA in the ventricular C.S.F. of patients suffering 
from Parkinsonism to be 186 ± 105 (S.D.) and 59 + 27 
mpg. /ml. C.S.F.) respectively, (table 2). These results 
have been calculated from the estimated concentrations 
of the acids in the preoperative (base line) samples of 
C.S.F. In more than two -thirds of all the cases these 
samples were obtained at stage I of the operation and 
in each case were the first 4 ml. of C.S.F. withdrawn 
from the patient. The remaining patients did not undergo 
stage I of the operation and the estimations were done 
on sample Bl of stage 2. Samples Al and Bl were 
comparable in that both were the first samples of C.S.F. 
withdrawn in the morning albeit two days apart, and that 
there had been no change in the treatment in the inter- 
vening period. There was, indeed, no significant 
difference (p00,1) between the mean concentrations of 
HVA and 5 -H1AA in sample Al and Bl in a small number of 
patients (8 cases) where this comparison was made. 
The ranges for the concentrations of the two acids 
in Parkinsonian patients were large. This was 
particularly marked for HVA, range 20 -500 mpg. /ml., 
and much less for 5 -H1AA : 20 -120 mpg. /ml., (table 2). 
Figure 1 shows the histograms of the frequency distribution 
for the acids in the C.S.F. of all the patients and it can 
be noted that for HVA there was a skewed distribution 
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for the higher concentrations while the distribution for 
5 -H1AA was relatively symmetrical. We have some evidence 
to believe that the estimates of HVA for the 3 patients 
showing the highest concentrations, i.e.> 375 mµg. /ml. 
O.S.F., were erroneously high. The results quoted were 
estimates done on sample Al and these showed an unusually 
poor correlation with the estimates of sample Bl, all the 
sample Bl estimates being less than 300 mµg. /ml. No 
apparent reason could be found for these discrepancies. 
It was observed that in two patients who gave a 
definite history of encephalitis the acid levels were 
extremely low. Another two patients, possibly of the 
post -encephalitic type of Parkinsonism, have been 
included in the small group of post -encephalitic 
Parkinsonism. The mean concentrations (mµg. /ml. O.S.F.) 
for these patients are HVA 64 ± 33 and 40 ± 18 for 5 -H1AA. 
It appeared, therefore, that this type of Parkinsonism 
could lead to particularly low levels of HVA in the O.S.F. 
HVA and 5-H1AA of control group. 
The mean concentration of HVA in the non -Parkinsonian 
patients was 447 ± 153 mµg. /ml. and that for 5 -H1AA : 
111 ± 50 mµg. /ml. These estimates were based on 15 
patients for the HVA and 17 patients for the 5 -H1AA 
(table 3). The range of concentrations for HVA was 
230 -670 mµg. /ml. and that for 5 -H1AA : 20 -200 mµg. /ml. 
The histograms for the frequency distribution (fig.l) 
of the acid concentrations in the control patients 
showed no definite peaks round the mean concentrations. 
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Table 1. Concentrations (mµg. /m1.) of homovanillic acid 
(HVA) and of 5- hydroxyindol- 3- ylacetic acid 
(5 -H1AA) in ventricular C.S.F. of Parkinsonian 
patients. 
The patients are listed in order of diminishing HVA 
concentrations. 
Explanatory notes - 
"Duration of illness" in years. 
"Tremor and rigidity" - graded 0 to + + ++ 
according to severity. 
upper line - right side 
lower line - left side 
"Grade" column - grade 1, unilateral Parkinsonism with 
tremor and /or rigidity. 
grade 2, bilateral Parkinsonism with 
tremor and /or rigidity 
grade 3, grade 2 with akinesia also 
present. 
"Drugs" - drugs administered have been referred to in 
main text. 
"Position of catheter" at time of sampling - 
R.V., right lateral ventricle 
L.V., left lateral ventricle 
III.V., third ventricle 
"Side of operation" - L, left 
R, right. 
"Type of operation" - T.P., destruction of ventrolateral 
nucleus of thalamus and 
globus pallidus. 
T., destruction of ventrolateral 
nucleus of thalamus. 
P., destruction of globus 
pallidus. 
M., Mundinger operation. 
C., Capsular lesion. 
t beside patient's number indicates history of encephalitis. 
" " in table indicates that no information was 
available about this parameter in this 
particular case. 
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Table 2 showing the mean concentrations(mµg. /ml.) of 
HVA and 5 -H1AA in patients with Parkinsonism and in 
control patients. 
Acids Parkinsonism Controls 
Homovanillic acid 186 t 105 (37)* 447 +,153 (15) 
5-hydroxyindol-3- 
ylacetic acid 59 ± 27 (32) 1 1 1 - 50 (17) 
The standard error of the difference between the two means: 
HVA 43,01 5 -H 1AA 12,97 
Observed differences between the means : 
HVA 261 5 -H1AA 52 
For HVA : observed difference approximately 6 times greater 
than standard error of difference i.e. highly, 
significant. 
For 5 -H1AA : observed difference is approximately 4 times 
greater than standard error of difference i.e. 
highly significant. 
* Mean concentration t Standard Duration (No. of patients). 
- 17 - 
The experimental difficulty in obtaining a sufficient 
number of control patients and the fact that the patients 
included had various pathological lesions of the brain, 
which, per se, could alter the C.S.F. acid concentrations, 
made the control group not entirely satisfactory. In 
addition, most of the patients of the control group were 
of a younger age -group than the Parkinsonian patients. 
The difficulty in restricting drug treatment before 
sampling C.S.F. in these patients, made changes in acid 
concentrations induced by drugs a possibility. It was 
striking how one patient, 6c (table 3), who was 
undergoing frontal lobectomy for aschizoid state showed 
persistently high levels for HVA, about 570 mµg. /ml. 
C.S.F., but extremely low levels, 20 mµg. /m1. for 
5 -H1AA. This is unlikely to be drug induced and it would 
be interesting if the low 5 -H1AA in the C.S.F. was 
associated with the patient's mental state. 
Com arison between Parkinsonian patients and "control" 
patients. 
The mean concentrations of HVA and 5 -H1AA in the 
ventricular C.S.F. of patients suffering from 
Parkinsonism were 40% and 53% respectively of those of 
the "control" group. For HVA the observed difference 
between the means of the two groups was approximately 
6 times greater than the standard error of the 
differences and for 5 -H1AA 4 times greater. The difference 
between the two groups of patients are, therefore, highly 
significant in respect of both acids, (p < 0,001). 
- 18 - 
Table 3. showing control group and acid concentrations. 
Patient No. Diagnosis 
Concentrations 
(mµg. /m1 C.S.F.) 













4c Cerebral abscess 320 190 
5c Subarachnoid haemorrhage - 200 
6c Schizoid state 570 20 
7c Subarachnoid haemorrhage 530 60 
8c Astrocytoma 600 90 
9c Cerebellar haemangio blastoma 500 145 
10c Head injury 410 80 
ll c Anxiety state 240 80 
12c Hydrocephalus 470 140 
13c Head injury 630 80 
14c Head injury 400 160 
15c Aqueduct stenosis 300 100 
16c Anxiety, phobias 230 85 
17c Hydrocephalus 240 60 
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Fig. 2. Regression line for the concentrations of 
5- hydroxyindol- 3- ylacetic acid (5 -H1AA) versus 
homovanillic acid (HVA) in Parkinsonian patient 
o - patients. 



















Correlation coefficient I r) : 
r_0.665 
( highly significant, i.e. at 0.1'1. 
10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 
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HVA and 5 -H1AA C.S.F. concentrations in patients with 
dystonias other than Parkinsonism. 
We have included a small study on the concentrations 
of HVA and 5 -H1AA in the ventricular C.S.F. of 5 patients 
who were undergoing stereotaxic surgery for the treatment 
of dystonias, but who were not suffering from Parkinsonism, 
as defined clinically. The results are shown in table 4. 
Four of these patients appeared to have concentrations of 
HVA and 5 -H1AA in the C.S.F. of the order of the upper 
part of the range for the concentrations of the acids in 
Parkinsonism. One case of spasmodic torticollis, 4d, 
table 4, showed acid concentrations within the range of 
those of the control group. 
We have not attempted any analysis of these results 
because of the small number of patients studied so far. 
Correlation uetween HVA and 5 -H1AA concentrations in 
the C.S.F. 
We have analysed the correlation between the 
concentrations of HVA and 5 -H1AA within the patients 
suffering from Parkinsonism, as well as the control 
cases. For the analysis, in the former group we had 
32 patients who had both HVA and 5 -H1AA estimated in 
the base -line samples, while we had 15 patients 
constituting the latter group, (table 5). 
The correlation coefficient (r = 0,665) for HVA and 
5 -H1AA in the Parkinsonian cases was highly significant 
(p < 0,001) . The regression line, "line of the best fit ", 
has been drawn in figure 2, which also demonstrates that 
for 
31 of the patients, the points representing the 
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Table 4. The concentrations of HVA and 5 -H1AA in C.S.F. 
in Dystonias other than Patkinsonism. 
Diagnosis Acid concentration 
(inig. /ml. C.S.F. ) 
HVA 5 -H1AA 
ld Torsion dystonia 275 50 
2d Torsion dystonia 180 75 
3d Familial tremor 180 80 
4d Spasmodic torticollis 770 125 
5d Spasmodic torticollis 240 60 
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Table 5. Mean concentrations of HVA and 5- H1AA(mµg. /ml.) 
in Parkinsonism and control group and the 
correlation coefficient between the two acids 




HVA 5 -H1AA acids 
Parkinsonism 192 t 110 (32)* 59 ± 27 (32) 0,665 
Control 447 t 148 (15) 105 ± 44 (15) 0,02 
* Mean concentration ± standard deviation (No.of patients). 
Significance test for r using t test: 
Parkinsonism: t = 4,87. This is highly significant, 
i.e. at 0,1% 
There was no correlation (r = 0,02) between HVA and 5 -H1AA 
in the patients of the control group. 
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Fig. 3. Correlation between concentrations of 
5- hydroxyindol- 3- ylacetic acid ( -H1AA) and 

























Correlation coefficient ( r): 
r = 0.02 
( ie. no corrilation) 
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correlation between the HVA and 5 -H1AA fall within ± 2 
Standard Errors of the regression line. 
In the control group we found no correlation between 
HVA and 5 -H1AA in the C.S.F. (r = 0,02). The wide 
scatter of the points is evident from fig. 3. 
Sampling of C.S.F. 
(I) Repeated sampling of C.S.F. at short intervals. 
When 3 samples of ventricular C.S.F. (the volume of 
each sample, as usual, 4 ml.) were withdrawn in rapid 
succession from some patients, there was usually a 
tendency for the acid concentrations to fall in the 
second and third samples. This was more evident in the 
case of HVA (table 6) where the mean concentration of 
the first sample (sample A1) was 174 
± 
139 and that of 
the third sample (sample A3) was 108 ± 24 mµg. /ml. while 
the corresponding results for 5 -H1AA were 53 35 and 
50 ± 32 mµg. /ml. respectively. The fall in the 
concentration of HVA with repeated sampling appeared to 
be more marked when the initial concentration was high. 
It appeared, therefore, that when comparing the 
results from various samples, it was important that the 
C.S.F. was withdrawn under comparable conditions. 
(II) Site of the catheter. 
The position of the sampling catheter was checked 
carefully, since there is evidence of marked concentration 
gradients for the acids within the C.S.F. compartments 
(Guldberg, Ashcroft and Crawford, 1966); and Ashcroft, 
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Table 6. The effect on the acid concentrations of 
withdrawing three 4 ml. samples of C.S.F., the 
samples being withdrawn in rapid succession. 
Sample HVA 5-H1AA 
Al 174 ± 139 (9)* 53 ± 35 (9) 
A2 143 ± 131 (9) 58 t 35 (9) 
A3 108 It 24 (9) 50 ± 32 (9) 
* Mean concentration(mpg. /ml. C.S.F) t S.D. (No.of patients). 
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Crawford, Eccleston, Sharman, MacDougall, Stanton, 
Binns, 1966). 
Unilateral Parkinsonism could provide a situation 
in which might occur the possibility of different acid 
concentrations in the two lateral ventricles. If the 
passage of substances did not take place freely between 
the two ventricles and only one side of the brain was 
affected, then a lower acid concentration might be 
expected on the affected side as compared to the 
unaffected side. In 6 patients with unilateral 
Parkinsonism in which the catheter was situated on the 
side of the lesion, the mean acid concentrations were: 
189 ± 128 mpg. /ml. for HVA and 63 ± 25 mpg. /ml. for 
5 -H1AA, (table 7). We have only 2 patients where the 
catheter was found to be on the opposite side to the 
lesion and the acid concentrations were for HVA 
188 mpg. /ml. and for 5 -H1AA 30 mpg. /ml. Although we 
need more results to give an unequivocal answer, it 
would appear not to matter which side the catheter was 
situated, possibly, because the acids equilibrated 
readily between the two compartments. 
In two cases of unilateral Parkinsonism where the 
catheter was situated in the third ventricle, the acid 
concentrations were not appreciably different from the 
lateral ventricular concentrations (table 7). Moreover, 
in the whole group of Parkinsonian patients (37 cases), 
the catheter was situated in the third ventricle in 9 
cases, but the mean acid concentration for those, HVA: 
167 ± 68 and 5 -H1AA: 50 ± 29 mpg. /ml., were not 
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significantly different from the mean of lateral ventricular 
C.S.F. concentration. ( p)0,1). 
Relationship between acid concentrations and some 
clinical data. 
Table 1 gives some clinical data along with the 
concentrations of HVA and.5 -H1AA in the ventricular C.S.F. 
of 37 patients of Parkinsonism studied. The patients 
have been listed in order of decreasing concentrations 
of HVA. We have analysed these results in some detail. 
(1) Age and sex. 
The patients were divided into three age -groups, 
40 -49 years, 50 -59 years and 60 -69 years. The mean 
concentrations of the acids for these groups are shown in 
table 8 and the highest age group showed the highest mean 
concentrations for both acids, but these were found not 
to be significantly different from those of the other 
groups (p>0,1). 
There was no significant difference in the mean acid 
concentrations for males and females suffering from 
Parkinsonism (table 9). 
(II) Duration of illness. 
In our series, none of the patients had suffered from 
Parkinsonism for less than 2 years and the patients have 
been divided into these groups: 2 -5 years, 6 -9 years 
and 10 or more years' duration of illness. Such a division 
gave fairly equal numbers of patients in each group, 
(table 10). 
There were no significant differences in acid 
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Table 7. The relationship in unilateral Parkinsonism 
between acid concentrations and the site of 
the catheter from which the C.S.F. sample 
was withdrawn. 




Same side as lesion 189 -, 128 (6)* 63 ± 25 (6)* 
Opposite side to lesion 190 and 185 (2) 30 (1) 
Third ventricle 290 and 90 (2) 100 and 20 (2) 
Mean concentration ± S.D. (No. of patients). 
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Table 8. Mean concentrations of HVA and 5 -H1AA in the 
O.S.F. in patients with Parkinsonism in 
different age groups. 
Mean concentrations (12111g. /ml.C.S.F.) 
Age groups HVA 5-H1AA 
40 - 49 years 179 ± 121 ( 7)* 55 ± 26 ( 4) 
50 - 59 years 161 ± 82 ( 17) 54 ± 26 (.15) 
60 - 69 years 233 ± 120 ( 12) 70 ± 28 ( 12) 
Mean concentration ± S.D. (No. of patients). 
Comparison of groups 50 -59 and 60 -69 years for both acids 
gave no significant difference between the groups(p > 0,1). 
Table 9. Showing mean concentrations of HVA and 5 -H1AA 
in males and females suffering from Parkinsonism. 
Sex HVA 5 -H1AA 
Males 177 ± 103 (24)* 57 ± 27 (20) 
Females 203 ± 113 (13) 63 28 (12) 
* Mean concentrations inmµg. /ml. 
patients). 
C.S.F. t S.D.(No. of 
Statistically, no significant differences between males 
and females, (p>0,1). 
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Table 10. Giving the mean concentrations for HVA and 
5- H1AA(mµg. /ml. C.S.F.) in groups of 
Parkinsonian patients with different duration 
of illness. 
Duration of illness HVA 5-H1AA 
2 - 5. years 209 ± 116 (13)* 61 26 (13) 
6 - 9 years 212 ± 109 (13) 78 ± 18 ( 9) 
10 and more years 129 ± 68 (11) 40 ± 21 (10) 
* Mean concentration ± S.D. (No. of patients). 
Statistical analysis for : 
HVA between groups 6 -9 and 10 + years, using Student's 
t test, p<0,05, hence the difference is significant. 
5 -H1AA between groups 6 -9 years and 10 + years 0,01 >p 
0,001, the difference is highly significant. 
There was no significant difference between the groups 
2 -5 and 6 -9 years in respect of either of the acids. 
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Table 11. Showing the mean concentrations(mµg. /ml.) of 
HVA and 5 -H1AA in Parkinsonian patients treated 
medically for their condition and on no drug 
treatment. 
H VA 5-H 1 AA 
Patients on no drugs 207 ± 135 (13)* 65 ± 28 (12) 
Patients on drugs 174 ± 88 (24) 56 ± 26 (20) 
* Mean concentration ± S.D. (No. of patients). 
p:0,1 in respect of both acids for the differences 
between the groups. 
Table 12. Showing the relationship between mean acid 
concentrations and degree of tremor, rigidity 
or akinesia - ranked groups - of Parkinsonian 
patients. 
Clinical Assessment 
0 and + 
Tremor 1) + ++ and + + ++ 
Tremor 2) 
0 and + 
+ ++ and + + ++ 
0 and + 
Rigidity 1) + ++ and + + ++ 
2)0 and + 





138 r 52 ( 3)* 50 + 32 ( 6) 
202 t 121 (19) 66 ± 27 (17) 
185 ± 107 ( 8) 59 ± 30 ( 6) 
196 ± 157 ( 9) 63 t 30 ( 9) 
174 ± 141 ( 5) 49 t 31 ( 5) 
175 t 81 (18) 59 t 25 (15) 
157 ± 117 ( 8) 46 It 31 ( 6) 
177 + 94 (10) 65 ± 14 ( 9) 
194 t 111 (19) 61±26 (17) 
178 ± 105 (18) 57 t 28 (15) 
* Mean concentration (mµg. /ml.) 
± S.D. (No. 
1) Tremor or rigidity of contralateral 
ventricular sample. 
2) Tremor or rigidity 
of the body. 
of patients). 
side to lateral 
ranking: 0 to + + + +) of either side 
There are no statistically significant differences in 
the mean acid concentrations in respect of severity of 
clinical symptoms. 
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Table 13. Showing mean concentrations of HVA and 5 -H1AA 
in groups of patients pre- and post -operatively. 
Groups Concentration(mµg. /ml.) 
in ventricular C.S.F. 
HVA 5-H1AA 

















Post- operative acid 
concentrations 
(immediate) 2) 
p+ 130 ± 88 (24) 54 ± 35 (20) 
Post - operative acid 
concentrations 
(3 days later) 3) 
0 ++ 210 ± 111 (15) 65 ± 38 (13) 
* Acid concentration ± S.D. (No. of patients). 
1) Samples Al or A2. 
2) Sample B3 (after coagulation of target area). 
3) Sample Cl from stage III of operation. 
+ The differences (Groups p) were not statistically 
significant (p > 0,1). 
++ The differences (Groups 0) were not significantly 
different (p>0,1). 
Patients in group p were sampled pre - operatively and 
post- operatively, immediately after the operation. 
Patients in group 0 were sampled pre- operatively 
and 
post -operatively, 3 days later. 
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Table 14. showing the mean concentrations of HVA in the 
caudate nucleus and lateral ventricular C.S.F. 








Concentration Ratio concentration 
C.N. to ventricu- 











* Bernheimer and Hornykiewicz, 1965. 
+ Own results. 
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concentrations between the groups 2 -5 and 6 -9 years for 
either of the acids (p> 0,1). However, the difference 
for the HVA concentration in groups 6 -9 and 10 or more 
years was significant (p<0,05) and the difference was 
highly significant for 5 -H1AA, (p< 0,01) . 
There did not appear to be any obvious correlation 
between duration of illness and the age of the patients. 
(III) Drugs. 
We did not obtain evidence that the medical treatment 
of Parkinsonism affected the acid concentrations since 
there was not a significant difference (p >0,1) between 
the patients who had been on treatment and those in 
whom all treatment had been stopped, (table 11). 
(IV) Relationship between symptomatology and acid 
concentrations. 
We attempted a correlation between biochemical 
findings and severity of tremor and rigidity and the 
presence or absence of akinesia by comparing the mean 
concentrations of HVA and 5 -H1AA in the C.S.F. of groups 
of patients, the groups having been determined by a 
separate rank order for tremor, rigidity and akinesia. 
Groups of patients with minimal tremor and groups with 
minimal rigidity were compared to the corresponding 
groups of severely affected patients, and groups of 
patients who had no evidence of akinesia compared to 
those with akinesia present. The results, shown in 
table 12, suggested that the concentrations of both 
acids tended to be higher in the groups of more severely 
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affected patients. For tremor and rigidity the 
differences appeared to become more evident if one 
compared the acid concentrations in the lateral ventricle 
to the contralateral limb signs rather than the overall 
assessment for both sides of the body. However, when 
the differences between the paired groups were subjected 
to statistical analysis, none of the differences were 
found to be statistically significant, (p>0,1 for all 
the paired differences). 
(V) Acid concentrations pre- and post -operatively. 
The effect on the acid concentrations of C.S.F. by 
the surgical treatment of coagulation of certain target 
areas was studied by analysing the differences in 
concentrations of HVA and 5 -H1AA pre- and post -operatively. 
We studied the effect on the acid concentrations both 
immediately following the coagulative destruction of 
target areas and 3 days later. The results are summarised 
in table 13, and there was clearly no difference in the 
mean concentrations for either acids when the pre -operative 
acid levels were compared to the acid levels 3 days after 
the definite operation, the difference between the means 
for HVA was 7 mpg. /ml. and for 5 -H1AA: 2 mµg. /ml. 
However, there appeared to be a fall in the concentrations 
of both acids immediately following the coagulation and 
for HVA the difference was not quite significant (p = 0,1) 
and for 5 -H1AA not significant (p> 0,1) . 
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DISCUSSION 
The study of cerebral metabolism in man has obvious 
difficulties. Most of the biochemical investigations on 
the cerebral amine metabolism in Parkinsonism have 
hitherto been based either on measurements of some amine 
and its acid metabolite content, post- mortem, of brain 
structures or on urinary excretion studies of these 
substances. For the purpose of biochemical investigations, 
the scope of human post -mortem work is limited and it is 
unlikely that urinary estimations of these compounds 
reflect. directly the levels in the brain. 
An approach which shows promising results, is the use 
of C.S.F. for the study of cerebral amine metabolism. 
It is, usually, feasible to obtain lumbar C.S.F. from 
patients, but the relationship between lumbar C.S.F. and 
brain concentrations of metabolites has still to be 
established (Ashcroft et al. 1966). We have relied upon 
analysis of ventricular C.S.F., drawing inferences about 
the cerebral metabolism based upon work in dogs which 
showed that changes in the acid metabolites in the 
ventricular C.S.F. of the dog reflect changes in the 
concentrations of the acids and parent amines in brain, 
particularly of the caudate nucleus (Guldberg, 1967 
and Guldberg and Yates, in preparation). 
The results reported here showed that the mean 
concentrations of HVA and 5 -H1AA in the ventricular 
C.S.F. of patients suffering from Parkinsonism was 
186 ± 105 (S.D.) and 59 ± 27 mµg /ml. C.S.F.respectively, 
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(table 2). When these results are compared to the control 
group (HVA mean 447 t 153 and 5 -H1AA mean 111 ± 
50 mkg. /ml.), it can be seen that there was a 2,4 fold 
reduction in HVA and a 1,9 fold reduction in 5 -H1AA 
concentration in Parkinsonism as compared to our control 
series. These differences are, statistically, highly 
significant in respect of both acids. The findings are 
in keeping with previously published data on the concen- 
tration of HVA in the caudate nucleus of post -mortem 
"control" subjects, 3,38 µg. /g. tissue (Bernheimer and 
Hornykiewicz, 1965), and of patients with idiopathic 
Parkinson's disease, 1,19 µg. /g. tissue (Bernheimer, 
Birkmayer, Hornykiewicz, Jellinger and Seitelberger,1965); 
this ratio being 2,8. There are no published data for 
the concentrations of brain 5 -H1AA in Parkinsonism, but 
our results showing a reduction of the levels in the 
C.S.F. were not unexpected since it has been reported 
that the concentration of 5- hydroxytryptamine in the 
brain is reduced (Bernheimer et al. 1961). 
We found a positive correlation (r = 0,665) between 
the concentrations of HVA and 5 -H1AA in the Parkinsonian 
patients; the results implying that the trend in the 
reduction of the HVA and 5 -H1AA concentrations in the 
C.S.F. was in the same direction for a significant number 
of patients (p < 0,001). There was, however, no 
correlation between the concentrations of HVA and 5 -H1AA 
in our control series, (r = 0,02). The reason for this 
is not under:;tood, but it may be related to the fact that 
the control series consisted of a group of patients with 
- 39 - 
a wide variety of pathological lesions, (table 3), some 
of which may be affecting dopamine and 5- hydroxytryptamine 
metabolism, or the egress of the metabolites, differentially. 
Also, the drug treatment of these patients prior to sampling 
f 
was not controlled. We obtained some evidence that drug 
treatment, especially anticholinergic drugs for the 
treatment of Parkinsonism, did not affect the acid levels 
in the Parkinsonian patients,(table 11), but some of the 
control patients received phenothiazines which are known 
to affect the levels of HVA, with minimal effect on 
5 -H1AA. This does, of course, make the validity of the 
results on our control patients doubtful. However, the 
mean concentration of HVA in human ventricular C.S.F. of 
about 450 mµg. /ml. for the controls is, probably, a 
reasonable estimate since in man the ratio between the 
mean concentration of HVA of the caudate nucleus and the 
ventricular C.S.F. can be estimated as 7,5 (table 14), 
and this compares with that of about 6,5 for the dog. 
We cannot make similar calculations for 5 -H1AA because 
there are no published results on concentrations of 
5 -H1AA in the relevant brain regions for man. The mean 
concentration of 5 -H1AA in the ventricular C.S.F. of 
the control patients (111 mµg. /ml.) is higher than that 
published by Ashcroft et al. (1966) for ventricular - 
drainage samples (88,1 mµg. /ml.). This is not surprising, 
however, since we know from our own dog experiments 
(Guldberg, 1967), and also for man in the case of HVA 
(table 6), that the concentrations of acid metabolites 
in the C.S.F. fall with frequent, repeated sampling of 
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ventricular C.S.F. 
The significance of the biochemical findings of low 
concentrations of HVA and 5 -H1AA, as well as their parent 
amines, dopamine and 5- hydroxytryptamine, in the brain of 
Parkinsonian patients is not known. They may be related 
to a diminished biosynthesis of the amines, but there are 
no published data on the metabolic turnover in the brain 
of dopamine and 5- hydroxytryptamine in Parkinsonism. 
The enzyme dopa decarboxylase does not appear to be 
affected in Parkinsonian brains (Bernheimer and 
Hornykiewicz, 1962), so it is unlikely that the conversion 
of dopa to dopamine, or of 5- hydroxytryptophan to 
5-hydroxytryptamine, is impaired, to account for the 
postulate of a diminished biosynthesis rate. Furthermore, 
there are, as yet, no published data suggesting a 
difference in tyrosine (3- hydroxylase activity between the 
brains of Parkinsonian patients and controls, which could, 
if that was the case, support the hypothesis of an altered 
turnover of dopamine in Parkinsonism. 
Another mechanism which is very important in 
determining the steady -state concentrations of dopamine 
and 5- hydroxytryptamine in the brain is the availability 
of binding sites for the amines. If there was a diminished 
ability of the Parkinsonian brain to store the amines, this 
would result in decreased amine concentrations in the brain. 
It is unlikely, however, that the storage mechanisms are 
at fault since this would lead to high, or possibly 
normal, acid levels, and not reduced acid concentrations 
as found in Parkinsonism. 
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The biochemical findings in Parkinsonism could be 
explicable in terms of a reduction,. by cell destruction, 
in the number of functioning neurones, the synthesis in 
these neurones remaining constant. The pathological 
changes in Parkinsonism are somewhat diffuse and variable 
and also they vary between the different forms of the 
disease (Denny -Brown, 1960), apparently, the cell -loss 
being most severe and diffuse in cases of post. -encephalitic 
Parkinsonism. Bernheimer and Hornykiewicz (1965) found 
the brain concentrations of HVA, as well as dopamine, 
to be particularly low in cases of post- encephalitic 
Parkinsonism. We have observed a similar trend in the 
C.S.F. concentrations in the small number of cases of 
this type which we have studied. It is apparent that 
the biochemical findings in Parkinsonism are not peculiar 
to that disease, and hence do not support the view of 
a specific error of metabolism, since a condition like 
senile dementia is also associated with low HVA concen- 
trations in the basal ganglia (Gottfries, Rosengren and 
Rosengren, 1965). Pathologically this condition is 
characterised by loss of neurones, and it would have 
been interesting to know if neurone loss correlated with 
the fall in HVA concentrations. We found that some 
dystonias other than Parkinsonism were associated with 
low HVA and 5 -H1AA concentrations in the C.S.F. but the 
relationship between the neuropathology of the various 
types of dystonias is not clear, and no comparison 
between neuropathological and biochemical findings can 
be made. 
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Parkinsonism is a progressive disease, and we obtained 
some evidence that in the group of patients whose illness . 
had been present 10 or more years, the concentrations of 
HVA and 5 -H1AA were even lower than in those patients in 
whom the illness had been present for a shorter period, 
(table 10). The levels of HVA and 5 -H1AA did not 
correlate with age or sex of the patients. 
The most consistent neuropathological finding in 
Parkinsonism is the degeneration of the melanin- containing 
nerve cells of the pars compacta of the substantia nigra, 
(Jung and Hassler, 1960). Support has been given, by the 
use of fluorescence microscopy, for the existence of 
nigro - striatal dopamine -containing fibres (Dahlstr6m 
and Fuxe, 1964). The cell bodies of these fibres are 
situated in the substantia nigra, mainly in the pars 
compacta, and electrolytic lesions in the substantia 
nigra resulted in loss of dopamine in the caudate nucleus, 
(Anden, Carlsson, Dahlström, Fuxe, Hillarp and Larsson, 
1964) . Our findings in Parkinsonism of the low HVA 
concentrations in the ventricular C.S.F. are explicable 
in terms of a fall in the concentration of the HVA of 
the caudate nucleus which resulted from the degeneration 
of dopaminergic cell bodies in the substantia nigra. 
The cause of the degeneration is unknown. We are not, 
as yet, certain to what extent brain regions other than 
the caudate nucleus contribute to the lateral ventricular 
C.S.F. levels of HVA. For 5 -H1AA it is unlikely that 
the caudate nucleus, containing relatively little 5 -H1AA, 
can account solely for the levels in lateral ventricular 
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C.S.F. In Parkinsonism the observations of lowered 
5 -H1AA levels in the C.S.F. may be a manisfestation of 
the more diffuse neuropathological destruction associated 
with the disease. 
The mechanisms operating in the production of the 
extrapyramidal symptomatology of Parkinsonism - tremor, 
rigidity and akinesia - are ill understood. Circumstantial 
evidence lends support to the hypothesis that dopamine 
plays a functional role in the extrapyramidal system. 
This evidence has largely been based on the regional 
distribution of dopamine in the brain, the highest concen- 
trations occurring in the basal ganglia, the localisation 
of the amine by fluorescence microscopy and the definite 
effects of drugs like reserpine and chlorpromazine on 
amine metabolism, drugs which may induce Parkinsonian- 
like states in man. The biochemical findings in 
Parkinsonism have added impetus to the work in this field. 
The beneficial effect of 1 -dopa - the precursor of 
dopamine - on the akinesia and rigidity of Parkinsonism 
has been established by several workers (Gerstenbrand 
and Pateisky, 1962; Hirschmann and Mayer, 1964; McGeer 
and Zeldowicz, 1964). We found, however, that there was 
no general correlation between HVA or 5 -H1AA concentrations 
in the C.S.F. and the severity of the rigidity or the 
presence or absence of akinesia. Poirier and Sourkes 
(1965) found that, in monkeys, destruction of the most 
dorsomedial fibres of the cerebral peduncle and the 
corresponding rubro- tegmento- spinal and nigrostriatal 
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tracts caused a Parkinson -like tremor as well as 
hypokinesia. This was associated with decreases in the 
concentrations of both dopamine and 5- hydroxytryptamine 
in the striatum. More recently, similar studies have 
shown that there was also a fall in the striatal HVA;. 
5 -H1AA was not measured (Sharman, Poirier, Murphy and 
Sourkes, 1967). In our series there was no significant 
correlation between the severity of tremor and the 
concentrations of HVA or 5 -H1AA in the C.S.F. The 
estimates did not appear to be affected by withdrawing 
the C.S.F. from the ventricle ipsilateral or contra - 
lateral to the patients` chief symptoms. 
We also attempted to assess the effect on the acid 
concentrations in the C.S.F.. of the stereotaxic operation 
for Parkinsonism. Destruction of the ventrolateral nucleus 
of the thalamus and /or globus pallidus did not appear to 
result in any alterations in the mean concentrations of 
HVA and 5 -H1AA in the C.S.F. 
The lack of any general correlation between the 
symptomatology of Parkinsonism and the concentration of 
HVA and 5 -H1AA in the ventricular C.S.F. as well as the 
lack of any effect of the operation on the acid levels, 
is difficult to explain. Indeed, in some patients 
severely affected by tremor, rigidity and akinesia the 
concentrations of HVA and 5 -H1AA were not outside the 
range of concentrations for the control patients. It is 
interesting to note that the most important drugs used 
in the medical management of Parkinsonism are,essentially, 
anticholinergic. 
4 J 
It seems possible, therefore, that the 'symptomatology 
might arise from an imbalance between the activities of 
the two opposing neural systems involving acetylcholine 
on the one hand and dopamine and, possibly, 5 hydrotrypt- 
amine on the other. There is no direct experimental 
evidence for this hypothesis. We do, of course, need 
to know more about acetylcholine of the basal ganglia in 
Parkinsonism, and we are hoping it might be possible to 
approach this problem from the point of view of C.S.F. 
studies on acetylcholine metabolism. Further investi- 
gations are also needed in the laboratory animal to try 
to establish to what extent brain structures not 
immediately adjacent to the lateral ventricles contribute 
to the acid levels of the C.S.F. Surgical destruction 
of the globus pallidus did not affect the acid C.S.F. 
levels in the Parkinsonian patients, and it may be that 
this is so because there is no relationship between the 
two sites as regards the acid concentrations. So far 
the evidence merely points to a definite relationship, 
in dogs, between the HVA concentrations in the caudate 
nucleus and the lateral ventricular C.S.F. In a further 
study of Parkinsonian patients we are assessing the 
relationship between the concentrations of HVA and 
5 -H1AA in the lumbar C.S.F. and the ventricular C.S.F. 
If a definite relationship exists, it would be helpful 
in reaching a long term assessment of the changes in 
concentrations, particularly the changes following 
stereotaxic surgery, obviously because one could then 
do lumbar estimations. 
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SUMMARY 
We have some evidence that the concentrations of HVA 
and 5 -H1AA in the C.S.F. of the lateral ventricles may 
reflect the brain metabolism of the parent cerebral 
amines, dopamine and 5- hydroxytryptamine. There appears 
to be a definite rblationship between the concentrations 
of HVA in the lateral ventricular C.S.F. and the caudate 
nucleus of dogs and man. (Guldberg, 1967). An approach 
based on this knowledge has been used in the analysis 
of ventricular C.S.F. samples of patients undergoing 
the ste re otaxic operation for the relief of Parkinsonism. 
The concentrations of HVA and 5 -H1AA were determined in 
the ventricular C.S.F. of Parkinsonian patients and a 
control group. There was a significant difference in 
the mean levels of both metabolites in the 2 groups of 
patients. The lower levels of the acid metabolites 
found in the group of Parkinsonian patients has been 
discussed in the light of our knowledge on the 
biochemistry of Parkinsonism. We have suggested that 
the biochemical findings could be explained on the basis 
of the neuropathological destructions occurring in the 
disease process and that they are not necessarily 
indicative of a primary.error of the amine metabolism. 
Within the group of Parkinsonian patients, lower acid 
levels were recorded in the group of patients with 
symptoms of more than 10 years and also in the small 
number of post -encephalitic patients. In Parkinsonism 
there was no clear evidence of any association between 
- 1}7 
the mean levels of the metabolites and the following 
factors: age, sex, presence or absence of drug treatment 
and the degree of the clinical symptoms of tremor, 
rigidity or akinesia. The lack of correlation between 
clinical symptomatology and the acid levels is 
particularly interesting and we have discussed in some 
detail the most apparent reasons for this. It is hoped 
that further work might clarify some of the problems. 
- 48 - 
tE FLRENCE S . 
Andén, N. -E., Carlsson, A., Dahlstrom, A., 
Fuxe, K., Hillarp, N. -A., and Larsson, K. (1964). 
Life Sci., 3; 523 -530. 
Andén, N. -E., Roos, B.E., and Weidinius, B. (1963) 
Life Sci. 7; 448. 
Ashcroft, G.W., Crawford, T.B.B., Eccleston, D., 
Sharman D.F., MacDougall, B.J., Stanton, J.B. and 
Binns, J.K. (1966). Lancet, Nov., 1049. 
Ashcroft, G.W., Sharman, D.F. (1962). 
Brit. J.Pharmacol., 19; 153. 
Barbeau, A., Murphy, C.F. and Sourkes, T.L. (1961). 
Science, 133; 1706 -1707. 
Barbeau, A., and Jasmin, G. (1961). 
Rev. Canad. Biol., 20; 837 -838. 
Bernheimer, H., and Hornykiewicz, 0., (1964). 
Arch. Exp. Path. Pharmak. 247; 305. 
Bernheimer, H. and Hornykiewicz, 0., (1965). 
Klin. Wschr. 43; 711 -715. 
Bernheimer, H., Birkmayer, W. and Hornykiewicz, 0.,(1961). 
Klin. Wschr., 39; 1056 -1059. 
Bernheimer, H., Birkmayer, W. and Hornykiewicz, 0., 
(1966). Wien. klin. Wschr. 78; 417 -419. 
Bernheimer, H., Birkmayer, W., Hornykiewicz, 0., 
Jellinger, K. and Seitelberger, F. (1965). In: Internat. 
Neurolog.Congress No.8,Vienna.- Wiener Medizinische 
Akademie, Vol.4, part I, p.145 -8. 
Bernheimer H. and Hornykiewicz, 0. (1962). 
Arch. Exp. Path. Pharmak., 243; p.295 
Birkmayer, W. and Hornykiewicz, 0. (1961). 
Wien. klin. Wschr., 73; 787 -788. 
Bischoff, F. and Torres, A. (1962). Clin.Chem.,8; 370 -377. 
- 49 - 
Dahlstrom, A. and Fuxe, K. (1964). 
Acta Physiol. Scand. 62; Suppl. 232: 1 -5. 
Denny -Brown, D. (1960), Lancet, 2, 1099 -1105 and 1155 -1162. 
Ehringer, H. and Hornykiewicz, O. (1960). 
Klin. Wschr., 38; 1236 -1239. 
Gerstenbrand, F. and Pateisky, K. (1962). 
Wien Z. Nervenheilk., 20; 90. 
Gillingham, F.J., Watson, W.S.., Donaldson, A.A. and 
Naughton, J.A.L. (1960). Brit. Med. Journal, 
2; 1395 -1402. 
Gottfries, O.G. , Rosengren, A.I. and Rosengren, E. 
(1965). Acta Pharmacol. et Toxicol., 23; 36 -40. 
Greer, M. and Williams, C.M. (1963). Neurology,13; 73 -76. 
Guldberg, H.C., Ashcroft, W.G. and Crawford, T.B.B. 
(1966). Life Sci., 1571 -1575. 
Guldberg, H.C. (1967). Ph. D. Thesis. 
University of Edinburgh. 
Hirschmann, J. and Mayer, K. (1964). 
Deùtsch. Med. Wschr. 89; 1877 -1880. 
Hornykiewicz, 0. (1962). Deutsch. med. Wschr., 
87; 1807 -1810. 
Hornykiewicz, 0. (1963). 
Wien. klin. Wschr., 75; 309 -312. 
Hornykiewicz, 0. (1966). Pharmacol. Rev.,l8; 925 -964. 
Jung, R. and Hassler, R. (1966). Handbook of Physiology, 
sect. I., Vol. II., ed. by: J. Field, H.W. Magoun and 
V.E. Hall. American Physiol. Soc., Washington, D.C. 
McGeer, P.L. and Zeldowicz, L.R. (1964). 
Canad. Med. Ass. Journ., 90; 463 -466. 
Poirier, L.J. and Sourkes, T.L. (1965). 
Brain, 88; 181 -192. 
- 50 - 
Resnick, R.H., Gray, S.J., Koch, J.P. and Timberlake, W.H. 
(1962) . Proc. Soc. Exp. Biol.,If.Y., 110; 77 -79. 
Sharman, D.F., Poirier, L.J., Murphy, G.F. and 
Sourkes, T.L. (1967). Jan. J. Physiol. Pharmacol., 
57. 
- 51 - 
